Atacand and Skin hypertrophy - a phase IV clinical study of FDA data

Summary:

Skin hypertrophy is reported as a side effect among people who take Atacand (candesartan cilexetil), especially for people who are female, 50-59 old, also take Magnevist, and have Nuclear magnetic resonance imaging brain.

The phase IV clinical study analyzes which people have Skin hypertrophy when taking Atacand. It is created by eHealthMe based on reports of 21,732 people who have side effects when taking Atacand from the FDA, and is updated regularly.

What is Atacand?

Atacand has active ingredients of candesartan cilexetil. It is often used in high blood pressure. eHealthMe is studying from 22,473 Atacand users. Check the latest studies of Atacand.

What is Skin hypertrophy?

Skin hypertrophy (skin cells enlarges) is found to be associated with 589 drugs and 546 conditions by eHealthMe. Check the latest studies of Skin hypertrophy.

On Aug, 01, 2026

21,732 people reported to have side effects when taking Atacand.
Among them, 22 people (0.1%) have Skin hypertrophy.

Among these 22 people:

What is the gender of people who have Skin hypertrophy when taking Atacand? *

female: 68.18 %
male: 31.82 %

What is the age of people who have Skin hypertrophy when taking Atacand? *

What are other drugs people take besides Atacand? *

What are other side effects people have besides Skin hypertrophy? *

Nephrogenic Systemic Fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease): 20 people, 90.91%
Pain: 18 people, 81.82%
Mobility Decreased (ability to move is reduced): 15 people, 68.18%
Weakness: 13 people, 59.09%
Stress And Anxiety: 13 people, 59.09%
Joint Stiffness: 12 people, 54.55%
Skin Tightness: 12 people, 54.55%
Joint Contracture (a permanent shortening of a muscle or joint): 11 people, 50.00%
Emotional Distress: 11 people, 50.00%
Scar: 11 people, 50.00%

What are the existing conditions these people have? *

Pain: 7 people, 31.82%
Nuclear Magnetic Resonance Imaging Brain: 7 people, 31.82%
Diabetes: 6 people, 27.27%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 6 people, 27.27%
Anaemia (lack of blood): 6 people, 27.27%
Red Blood Cell Count Decreased: 2 people, 9.09%
Hyperkalemia (damage to or disease of the kidney): 2 people, 9.09%
Pain In Extremity: 1 person, 4.55%
Osteoporosis (bones weak and more likely to break): 1 person, 4.55%
Oedema Peripheral (superficial swelling): 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Atacand and have Skin hypertrophy?

- Check whether Skin hypertrophy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Atacand:

Atacand (22,473 reports)

Browse all side effects of Atacand:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Skin hypertrophy:

Skin hypertrophy (589 drugs)

Browse all the conditions that are associated with Skin hypertrophy:

Skin hypertrophy (546 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on candesartan cilexetil (the active ingredients of Atacand) and Atacand (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.